GSK vax plant gets warning letter; Sweetened Pfizer bid could nab AstraZeneca; Pfizer's Xeljanz reverses baldness;

@FiercePharma: Drugmakers in India trapped between price caps and shortage rules. More | Follow @FiercePharma

@TracyStaton: Here's @JohnCFierce's take on the Vertex VX-809/Kalydeco PhIII, including interview with CEO Jeff Leiden. Story | Follow @TracyStaton

@EricPFierce: Abbott, in Russia since 1978, knows the game, buys Veropharm to establish local production credentials. News | Follow @EricPFierce

@CarlyHFierce: Have YOU checked out the list of 15 Highest-Paid Biopharma CEOs of 2013? Report | Follow @CarlyHFierce

> A GlaxoSmithKline ($GSK) vaccine plant in Canada has been sent a warning letter from the FDA for manufacturing problems that could lead to microbial contamination. Warning Letter

> Forest Laboratories ($FRX) says that its antidepressant Viibryd performed significantly better than a placebo for generalized anxiety disorder, which could be boon for Actavis ($ACT), which is buying Forest. Story

> Merck ($MRK) has named Michael J. Holston to succeed Bruce N. Kuhlik as general counsel when he retires July 1, 2015. Release

> Analysts at BNP Paribas said in a note that if Pfizer ($PFE) would raise its £70 billion bid for AstraZeneca ($AZN) to £75 billion ($127.7 billion), they think it could pull off a deal to buy the U.K. company. Blog Post

> Jiangsu Hengrui Medicine, among China's biggest privately-owned drugmakers, says the FDA approved its oxaliplatin to treat colon and rectal cancer. Report

Medical Device News

@FierceMedDev: New fibroid-removal device provides less invasive alternative. News | Follow @FierceMedDev

@StacyALawrence: Apple, Google stalk wearable med tech with glucose monitoring up first. More | Follow @StacyALawrence

@MichaelGFierce: Sinus drug delivery startup Intersect ENT files for $80 million IPO. Story via Silicon Valley Business Journal | Follow @MichaelGFierce

@EmilyWFierce: California's high court rules that large retailers don't need to keep external defibrillators on hand for customers. Story via LA Times | Follow @EmilyWFierce

> Philips launches image-guided neurology surgical tech in Europe. More

> Medtronic rebuffed by SCOTUS in pain-pump lawsuit. Story

Biotech News

@FierceBiotech: Merck targets Alzheimer's in $526M collaboration on new cognitive treatment. More | Follow @FierceBiotech

@JohnCFierce: Biotech star Bosley takes the helm at Editas. Item | Follow @JohnCFierce

@DamianFierce: Shire's Ornskov isn't sweating AbbVie, keeping up with the World Cup. Story (The Danish Dynamite didn't qualify.) | Follow @DamianFierce

@EmilyMFierce: Mersana partners with EMD Serono to advance ADC platform. Article | Follow @EmilyMFierce

> Ohr touts visual acuity results as PhII eye study fails primary goal. Story

> Biotechs queue up for $269M in fresh IPOs amid a sector rebound. Article

> EY: R&D budgets soar as cash-laden biotechs spend big on research. More

Biotech Research News

> UC San Diego to lead $2M statewide brain research project. More

> NIH awards U. of Buffalo $4.4M to repurpose old antibiotics. Story

> Novartis MS drug Gilenya could relieve painful side effect of chemo. Article

> UPenn team IDs potential target for treating Type 1 diabetes. News

> Mersana partners with EMD Serono to advance ADC platform. Report

Pharma Manufacturing News

> Carlyle buys Japanese contract manufacturer Sunsho. More

> West Pharmacuetical readies its first India injectables packaging plant. Article

> Abbott gets local production cred with deal to buy Russia's Veropharm. News

> Drugmakers in India trapped between price caps and shortage rules. Report

> Aesica plant in Italy responds as China's track and trace rules come into play. Story

> GSK vaccine plant in Texas about a year away. Item

And Finally... Researchers say a man give Pfizer's ($PFE) rheumatoid arthritis drug Xeljanz to treat his plaque psoriasis and alopecia universalis, a rare auto-immune disease which causes loss of body hair, grew a full head of hair in 8 months of treatment. Story

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.